Best Viral Vector CDMOs by Signal Score

· updated as new inspection, certificate, and trial data enters the platform
← All Viral Vector CDMOs Best Clean FDA History Commercial Scale
Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China
10
CDMOs tracked
10
Fully scored
7
With FDA records
24
FDA inspections
90
EMA/MHRA GMP certs

Viral vector CDMOs manufacture the three GMP-relevant vector platforms used in modern gene therapy and gene-modified cell therapy: adeno-associated virus (AAV), lentivirus, and adenovirus. Each platform has distinct process, containment, and analytics requirements, and CDMOs typically specialize in one or two platforms rather than all three. Platform is the first shortlist filter in any viral vector procurement decision.

This ranking aggregates every CDMO tracked as a viral vector manufacturer across the three platforms. For platform-specific rankings with process-critical detail (BSL-2 containment for lentivirus, full/empty capsid analytics for AAV, high-titre transient expression for adenovirus), use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors integrating vector supply with downstream cell processing (CAR-T, gene-modified HSC), the <a href="/modality/cell-and-gene-therapy">cell &amp; gene therapy view</a> extends this list with cell therapy CDMOs.

FDA inspection outcomes across these CDMOs: 12 NAI (no action), 12 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (26), United States (22), Denmark (18), Austria (9), Ireland (9).

Last updated 2026-07-11. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
 83.1 97.9 6 insp · 10 GMP Available 2 programs
2
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
 80.6 99.9 2 insp · 23 GMP Available 2 programs
3
TK
Takeda
Boston, MA · Zurich, CH
 80.5 99.3 4 insp · 18 GMP — 100 programs
4
Lonza
Basel, Switzerland
 78.2 95.1 2 insp · 8 GMP — 1 programs
5
OX
Oxford Biomedica
Oxford, United Kingdom
 77.1 100.0 0 insp · 13 GMP Available 7 programs
6
CI
Cincinnati Children's Vector Production Facility
Cincinnati, OH
 75.2 100.0 1 insp · 0 GMP — 1 programs
7
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
 73.4 97.7 1 insp · 0 GMP Available 9 programs
8
RT
ReiThera
Rome, IT
 71.1 100.0 0 insp · 4 GMP — 1 programs
9
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
 91.7 98.7 8 insp · 11 GMP Limited 0 programs
10
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
 88.0 100.0 0 insp · 3 GMP — 0 programs
How we score CDMOs →

What to evaluate in a Viral Vector CDMO

Vector platform match
First shortlist filter for any viral vector program is platform. AAV for in vivo systemic, lentiviral for ex vivo cell engineering, adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within.
Facility-level regulatory record on the platform
A CDMO's strong FDA record on AAV does not automatically de-risk their lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use, not the CDMO's aggregate score.
Analytics maturity per vector
Full/empty capsid separation for AAV, RCL testing for lentivirus, particle-to-infectivity ratio for adenovirus — each platform has non-negotiable release-testing requirements. A CDMO's qualified, validated assay panel for the specific vector is the single most under-appreciated cost driver in viral vector programs.
Capacity match to phase and dose
AAV early clinical runs at 50-200L, commercial at 1,000-2,000L single batch; lentiviral commercial supply is a narrower field with per-patient-dose economics. Confirm the CDMO's capacity headroom at your target phase before shortlisting — capacity constraints appear late and derail commercial launches.

Viral Vector CDMOs — Frequently Asked Questions

Who are the top Viral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Viral Vector CDMOs include Thermo Fisher Scientific, AGC Biologics, Takeda. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Viral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 7 Viral Vector CDMOs with FDA inspection records and 90 EMA/MHRA GMP certificates across the group.
What should I look for in a viral vector CDMO?
Match the vector platform first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, vector-specific analytics maturity, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific technical detail worth reading before finalizing a shortlist.
How many viral vector CDMOs does CDMO Signal track?
65+ CDMOs are tracked across the three GMP viral vector platforms — the union of AAV, lentiviral, and adenoviral manufacturers, deduplicated. Each is scored independently on the standard four-pillar Signal Score composite.
How is viral vector manufacturing different from mAb or recombinant protein biologics?
Viral vector manufacturing shares the mammalian cell culture upstream backbone with biologics but diverges sharply on downstream. Viral vector downstream requires enveloped/non-enveloped virus purification (chromatography, tangential flow filtration, ultracentrifugation) rather than protein A affinity capture. Analytics differ fundamentally — infectious titer and capsid analytics for viral vectors vs product-related impurities for biologics. Regulatory paths also differ: viral vectors carry additional biosafety review (RCL for lentivirus, adventitious agents for all platforms) beyond standard biologics.
Related modalities
AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Adenoviral Vector CDMOs Cell Therapy CDMOs Gene Therapy CDMOs Cell & Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy